Calling all investigators focused on addressing elimination in HIV/HCV co-infected and high-risk individuals! Gilead’s HIV/HCV No Co-Infection (NoCo) Program intends to support these micro-elimination efforts by giving up to $600,000 per research proposal.
The Letter of Intent submission window closes Monday 8/20. To find out more about the HIV/HCV NoCo Program, and to submit, click here.
Conducted at the request of the Department of Health and Human Services’ Office of Infectious Disease and HIV/AIDS Policy (OIDP), this report identifies the barriers to greater integration of OUD and infectious disease services and Read more…
On September 10, 2019, the Centers for Disease Control and Prevention (CDC) released their 2017 Viral Hepatitis Surveillance Report. The report comes after the World Health Assembly in 2016, where the United States agreed to Read more…
The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence review on screening for hepatitis C virus infection in adolescents and adults. The Draft Recommendation Statement and Draft Evidence Read more…